Modality
Peptide
MOA
PD-L1i
Target
CD3
Pathway
T-cell
Pancreatic CaCervical CaSMA
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
~Jan 2020
→ ~Apr 2021
Phase 3
Jul 2021
→ Apr 2031
Phase 3Current
NCT06616759
474 pts·Pancreatic Ca
2021-07→2029-02·Recruiting
NCT04157103
2,253 pts·Pancreatic Ca
2023-07→2031-04·Terminated
2,727 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-11-047mo awayPh1 Dose Esc· SMA
2029-02-132.9y awayPh3 Readout· Pancreatic Ca
2031-04-115.0y awayPh3 Readout· Pancreatic Ca
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Recruit…
P3
Termina…
Catalysts
Ph1 Dose Esc
2026-11-04 · 7mo away
SMA
Ph3 Readout
2029-02-13 · 2.9y away
Pancreatic Ca
Ph3 Readout
2031-04-11 · 5.0y away
Pancreatic Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06616759 | Phase 3 | Pancreatic Ca | Recruiting | 474 | DAS28 |
| NCT04157103 | Phase 3 | Pancreatic Ca | Terminated | 2253 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| 207-5197 | Samsung Biologics | Approved | BET |